Farallon Capital Discloses 5.1% Stake in InflaRx N.V. (IFRX)

On May 14, 2026, a group of reporting persons led by Farallon Capital Management, L.L.C. filed a Schedule 13G regarding their holdings in InflaRx N.V. (IFRX). The filing indicates that various Farallon-affiliated funds and individual managing members collectively beneficially own 7,500,000 ordinary shares, representing a 5.1% ownership stake in the company. The reporting persons include Farallon Capital Partners, L.P., Farallon Partners, L.L.C., and several individual managing members such as Joshua J. Dapice, Philip D. Dreyfuss, and Hannah E. Dunn. This position was established or reached the reporting threshold on May 7, 2026. The shares are held directly by various Farallon Funds, with Farallon Partners, L.L.C. acting as the general partner for several of these entities. The filing was made under Rule 13d-1(c), certifying that the shares were not acquired for the purpose of changing or influencing the control of the issuer. This represents a significant new institutional position in the biopharmaceutical company.